Experienced in Retinoblastoma

Dr. Mrinal M. Gounder

Oncology
Memorial Solid Tumor Group
1275 York Ave, 
New York, NY 
Offers Telehealth
Experienced in Retinoblastoma
Memorial Solid Tumor Group
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mrinal Gounder is an Oncologist in New York, New York. Dr. Gounder is rated as an Experienced provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Epithelioid Sarcoma, Liposarcoma, and Liver Embolization.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Retinoblastoma.

Specialties
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MEMORIAL SOLID TUMOR GROUP
1275 York Ave, New York, NY 10065
Other Locations
MEMORIAL SOLID TUMOR GROUP
160 E 53rd St, New York, NY 10022

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: GSK3326595, Pembrolizumab
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients with Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: TP-1287
Study Phase: Phase 1
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Enrollment Status: Completed
Publish Date: June 07, 2023
Intervention Type: Other, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: Oraxol
Study Phase: Phase 2
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Enrollment Status: Completed
Publish Date: March 01, 2023
Intervention Type: Drug
Study Drug: Tegavivint
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 9 Less Clinical Trials

120 Total Publications

Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.
Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.
Journal: Future oncology (London, England)
Published: September 01, 2025
Similar Doctors
Elite in Retinoblastoma
Dr. Jasmine Francis
Hematology | Oncology
Elite in Retinoblastoma
Dr. Jasmine Francis
Hematology | Oncology

Mskcc Surgery Group

160 E 53rd St, 
New York, NY 
 (0.8 miles away)
212-610-0496
Languages Spoken:
English
See accepted insurances

Jasmine Francis is a Hematologist and an Oncologist in New York, New York. Dr. Francis is rated as an Elite provider by MediFind in the treatment of Retinoblastoma. Her top areas of expertise are Retinoblastoma, Melanoma of the Eye, Metastatic Uveal Melanoma, Vitrectomy, and Liver Embolization.

Advanced in Retinoblastoma
Dr. Sarah J. Easaw
Oncology | Hematology
Advanced in Retinoblastoma
Dr. Sarah J. Easaw
Oncology | Hematology
1255 Route 70, 31 S, 
Lakewood, NJ 
 (50.4 miles away)
732-961-0010
Languages Spoken:
English, Malayalam
See accepted insurances
Accepting New Patients

Sarah Easaw is an Oncologist and a Hematologist in Lakewood, New Jersey. Dr. Easaw is rated as a Distinguished provider by MediFind in the treatment of Retinoblastoma. Her top areas of expertise are Myelodysplastic Syndrome (MDS), RUNX1 Familial Platelet Disorder, Paget Disease of the Breast, and Breast Cancer. Dr. Easaw is currently accepting new patients.

Helena A. Yu
Advanced in Retinoblastoma
Dr. Helena A. Yu
Oncology
Advanced in Retinoblastoma
Dr. Helena A. Yu
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Helena Yu is an Oncologist in New York, New York. Dr. Yu is rated as an Elite provider by MediFind in the treatment of Retinoblastoma. Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gounder's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 15 Distinguished Conditions
View All 10 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile